AMR Stakeholder Profile
ENABLE – European Gram-negative Antibacterial Engine
Focus area/active in: Human Health | Therapeutics
Company/Organisation type: Association | Cluster | Network
About:
ENABLE is a fully functional drug development platform that provides non-dilutive funding for European SMEs and research groups to work in collaboration with partners to progress anti-infective Gramnegative compounds and bring them into clinical trials. It is a public-private partnership collaboration in which EFPIA companies, SMEs, academia and independent experts join forces. In January 2020, the ENABLE project has achieved its initial goals to i) identify 3 antibacterial leads, ii) select 2 antibacterial development candidates and iii) advance 1 compound into preclinical and Phase I clinical studies. With several promising compounds in the pipeline, IMI granted the project a one year no-cost extension. The ENABLE programme portfolio can continue to benefit from the expertise and financing until January 2021. New Expressions of Interest will not be accepted.
Get in touch!
Please fill out the form below to get in touch with us.